康复新液联合思密达防治急性放射性食管炎

目的观察康复新液联合思密达防治急性放射性食管炎的效果。方法69例NSCLC患者随机分为两组。治疗组37例，在第1次放疗摆位时口含康复新恩密达悬浊液（康复新液10ml＋思密达3g），摆位结束后缓缓咽下（尽量避免吞咽动作）；每次放疗时均服用，放疗期间每晚睡前再次含咽，直到放疗结束。对照组32例，思密达悬浊液（思密达3g＋温水10m1），服用方法同治疗组。结果治疗组和对照组急性放射性食管炎的发生时间分别为放疗后（18．4±0．5）d和（14．3±0．4）d，（P〈0．05）；治疗组和对照组急性放射性食管炎的发生率分别为13．5％和28．1％（P〈0．05）；治疗组和对照纽发生急性放射性食管炎后的治疗总有效率分别为100％和88．9％（P〈0．05）。结论康复新液联合思密达能明显推迟急性放射性食管炎的发生率，降低发生率，同时降低其严重程度，并且发生急性放射性食管炎后的治疗总有效率较单用恩密达高。

Kangfuxin plus Smida regimen in preventing acute esophagitis

Objective To evaluate the effect of Kangfuxin plus Smida regimen in preventing acute esophagitis. Methods. 69 patients with NSCLC by radiotherapy were divided randomly into two groups. Regimens：Treatment group（37 cases）was given Kangfuxin plus Smida 2 times a day , slowly swallow;Control group（32 cases）was given Smida alone as same as the treatment group. Results The commencement time of acute esophagitis of the treatment group was （ 18.4±0. 5 ） days, and the one of the control group was（ 14. 3±0. 4） days. The rate of acute esophagitis of the treatment group wasl3.5% ,and the one of the control group was 28.1%. The rate of total curement of the treatment group was 100% ,and the one of the control group was 88.9%. The difference of all the above between the two groups was significant （ P〈0.05 ）. Conclusion Kangfuxin plus Smida regimen was effective and better reliable in preventing acute esophagitis.